Email ID
Password
Scrip   
Hisamitsu gains close to 90% of Noven in first tender
25 August 2009
Ian Haydock

Hisamitsu had secured an 87.4% holding in Noven Pharmaceuticals at the August 19th close of its initial tender offer for the US firm, paving the way for a full acquisition.

Investors responded enthusiastically to the $16.50 per share offer, which represented a 22% premium to Noven's closing...



Please Login to read the full article.
JOB OF THE WEEK Promote your vacancy here
© 2010 Informa plc. All rights reserved.
This site is owned and operated by Informa plc ("Informa") whose registered office is Mortimer House, 37-41 Mortimer Street, London, W1T 3JH. Registered in England and Wales. Number 3099067. UK VAT Group: GB 365 4626 36